In addition, despite the discovery of numerous p53-based drugs, p53 genetic mutations have been considered as genetic biomarkers for predicting treatment response, as outlined in the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for the treatment of patients with p53 mutant cancers, including lung cancer, breast cancer, and acute myeloid leukemia [42]. This evidence concerns the gene TP53 and cancer.